Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, blood vessels, and lymphatic tissue (mesenchymal cells). Despite being ...
The ex vivo cartilage defect model was prepared from cartilage harvested from the KRS patients’ excised knee joints. Only cartilage from the mid-region of the lateral-femoral compartment ...
December 2024, immediately following the approval of the world's first mesenchymal stromal cells clinical trial, the U.S. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback